More than 8000 patients
have been treated with the assistance of BEBIG
More than 30 000 Russian microsourses
are produced since the launch of our production
29 Medical Centers
29 brachytherapy consulting rooms were set up in Russian medical centres with the assistance of BEBIG
Iodine-125 microsources for the treatment of prostate cancer
BEBIG was founded in 2004 in order to introduce high-tech and innovative cancer treatment methods into Russian medical practice.
The main task of the company was to promote the low-dose brachytherapy method based on iodine-125 for the treatment of prostate cancer.
The company received the support of RUSNANO in March 2008 for financing a project for the production of domestic microsources with iodine-125. The RUSNANO application was preceded by several years of hard work: research and development, and analysis of demand and market prospects.
During the research and development stage, BEBIG received huge support from the Foundation for Assistance to Small Innovative Enterprises in Science and Technology. In late 2006 - early 2007, the foundation began to fund research and development for the project: BEBIG LLC - Development of iodine-125 microsources for the treatment of prostate cancer. Duration of research and development – 3 years.
In 2014, BEBIG launched the first factory in Russia for the production of iodine-125 microsources for low-dose brachytherapy under licence of Eckert & Ziegler BEBIG, the leading German manufacture of medical products and equipment for brachytherapy. In June 2014, the first factory for the production of microsources for the treatment of prostate cancer was launched under licence from this major manufacturer. The necessary facilities were built for the production of microsources in accordance with GMP requirements (about 100 m2), and the corresponding equipment was prepared. Production capacity not only ensured that demand for microsources was 100% satisfied for all Russian institutions but also allowed the company to enter new markets.
The acquired microsource production technology is of great social significance, as a product has been obtained which is cheaper than foreign analogues and which allows this treatment method to be used by a wide range of medical institutions. This means that it will be possible to cure many more men suffering from prostate cancer.
With the assistance of BEBIG, 29 brachytherapy consulting rooms were set up in Russian medical centres, in Armenia and Kazakhstan. More than 8000 patients have been treated.
The company plans in the near future to launch its own production line of nanostructured yttrium-90 microspheres, which are used in treating primary and metastatic liver cancer and prostate cancer.